Description
Sexually acquired oncogenic Human Papillomavirus
(HPV) types are important co-factors in the development of
anogenital tract malignancies. HPV vaccines are a major
primary prevention strategy against cervical cancer, other
HPV-associated malignancies, cervical dysplasia and genital
warts. Improving vaccination uptake is key to the future
success of the HPV vaccination programme, and could
potentially be achieved by involving GPs, sexual health
services and providers in its delivery.
